Galmed Pharmaceuticals (GLMD) PT Lowered to $6 at Maxim Group, Following Earnings
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Price: $0.51 -1.92%
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy lowered the price target on Galmed Pharmaceuticals (NASDAQ: GLMD) to $6.00 (from $10.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Galmed's Aramchol shows added cell death in prostate cancer study
- Citi Upgrades a2 Milk Co (A2M:AU) (ACOPF) to Buy
- Mitsubishi Gas Chemical Co Inc (4182:JP) PT Lowered to JPY5,600 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Maxim Group, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
